Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma
The activity of mitoxantrone in patients with pretreated aggressive non-Hodgkin’s lymphoma (NHL) has been demonstrated in several phase II studies [1–3]. In a previous phase II trial, the present authors investigated the efficacy of mitoxantrone combined with cytarabine (Ara-C) in conventional doses for patients with refractory disease , but the response rates did not seem to have improved as compared with mitoxantrone alone. Encouraging results have been reported on the use of high-dose Ara-C alone in relapsed NHL [5–7]. In patients with refractory acute leukemia, the combination of high-dose Ara-C and mitoxantrone has been shown to be active [8, 9]. We have initiated a series of studies with this combination for refractory NHL.
KeywordsToxicity Lymphoma Leukemia Oncol Neutropenia
Unable to display preview. Download preview PDF.
- 2.Gams RA, Steinberg J, Posner L (1984) Mitoxantrone in malignant lymphoma. Sem-in Oncol 1 [Suppl] 47–49Google Scholar
- 9.Hiddemann W, Büchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzenburg S, Donjuijsen-Ant R, Lengfelder E, Hoelzer D (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone ( HAM ). Leukemia 4: 637–640PubMedGoogle Scholar
- 15.Thiel E, Gerhartz HH, Brittinger G (1988) Response-adapted COP-BLAM/IMVP-16 chemotherapy for advanced stage aggressive non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 7: 244Google Scholar
- 19.Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andrcesen R, Fiedler W, Frisch J, Schulz G, Hunstein W (1990) Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin’s lymphoma. Cancer 66: 423–430PubMedCrossRefGoogle Scholar